Search

Your search keyword '"Schiavoni, M."' showing total 211 results
Start Over Author "Schiavoni, M."
211 results on '"Schiavoni, M."'

1. Brillouin propagation modes in optical lattices: interpretation in terms of nonconventional stochastic resonance

Author

Sanchez-Palencia, L., Carminati, F. -R., Schiavoni, M., Renzoni, F., and Grynberg, G.

Subjects
Physics - Atomic Physics
Abstract

We report the first direct observation of Brillouin-like propagation modes in a dissipative periodic optical lattice. This has been done by observing, in both theoretical and experimental work, a resonant behaviour of the spatial diffusion coefficient in the direction corresponding to the propagation mode with the phase velocity of the moving intensity modulation used to excite these propagation modes. Furthermore, we show theoretically that the amplitude of the Brillouin mode is a nonmonotonic function of the strength of the noise corresponding to the optical pumping, and discuss this behaviour in terms of nonconventional stochastic resonance., Comment: Phys. Rev. Lett., accepted for publication

Published
2002
Full Text
View/download PDF

2. Temperature and spatial diffusion of atoms cooled in a 3D lin$\perp$lin bright optical lattice

Author

Carminati, F. -R., Schiavoni, M., Sanchez-Palencia, L., Renzoni, F., and Grynberg, G.

Subjects
Physics - Atomic Physics
Abstract

We present a detailed experimental study of a three-dimensional lin$\perp$lin bright optical lattice. Measurements of the atomic temperature and spatial diffusion coefficients are reported for different angles between the lattice beams, i.e. for different lattice constants. The experimental findings are interpretated with the help of numerical simulations. In particular we show, both experimentally and theoretically, that the temperature is independent of the lattice constant., Comment: accepted for publication in Eur. Phys. J. D

Published
2001
Full Text
View/download PDF

8. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET

Author

Castaman, G., Santoro, C., Coppola, A., Mancuso, M. E., Santoro, R. C., Bernardini, S., Pugliese, F. R., Lubrano, R., Golato, M., Tripodi, A., Rocino, A., Santagostino, E., Biasoli, C., Borchiellini, A., Catalano, A., Contino, L., Coluccia, A., Cultrera, D., De Cristofaro, R., Di Minno, G., Fabbri, A., Franchini, M., Gamba, G., Chiara, A., Gresele, P., Giampaolo, A., Hassan, H. J., Luciani, M., Marchesini, E., Marino, R., Mazzucconi, M. G., Molinari, A. C., Morfini, M., Notarangelo, L. D., Peccarisi, L., Peyvandi, F., Pollio, B., Rivolta, G. F., Ruggieri, M. P., Sargentini, V., Schiavoni, M., Sciacovelli, L., Serino, M. L., Siragusa, S., Tagliaferri, A., Testa, S., Tosetto, A., Zampogna, S., Zanon, E., Castaman, Giancarlo, Santoro, Cristina, Coppola, Antonio, Mancuso, Maria E, Santoro, Rita C, Bernardini, Sergio, Pugliese, Francesco R, Lubrano, Riccardo, Golato, Maria, Tripodi, Armando, Rocino, Angiola, Santagostino, Elena, Biasoli, Chiara, Borchiellini, Alessandra, Catalano, Alberto, Contino, Laura, Coluccia, Antonella, Cultrera, Dorina, De Cristofaro, Raimondo, Di Minno, Giovanni, Fabbri, Andrea, Franchini, Massimo, Gamba, Gabriella, Giuffrida, Anna Chiara, Gresele, Paolo, Giampaolo, Adele, Hassan, Hamisa J, Luciani, Matteo, Marchesini, Emanuela, Marino, Renato, Mazzucconi, Maria Gabriella, Molinari, Angelo C, Morfini, Massimo, Notarangelo, Lucia D, Peccarisi, Lucia, Peyvandi, Flora, Pollio, Berardino, Rivolta, Gianna Franca, Ruggieri, Maria Pia, Sargentini, Vittorio, Schiavoni, Mario, Sciacovelli, Laura, Serino, Maria Luisa, Siragusa, Sergio, Tagliaferri, Annarita, Testa, Sophie, Tosetto, Alberto, Zampogna, Stefania, Zanon, Ezio, Castaman, G., Santoro, C., Coppola, A., Mancuso, M. E., Santoro, R. C., Bernardini, S., Pugliese, F. R., Lubrano, R., Golato, M., Tripodi, A., Rocino, A., Santagostino, E., Biasoli, C., Borchiellini, A., Catalano, A., Contino, L., Coluccia, A., Cultrera, D., De Cristofaro, R., Di Minno, G., Fabbri, A., Franchini, M., Gamba, G., Chiara, A., Gresele, P., Giampaolo, A., Hassan, H. J., Luciani, M., Marchesini, E., Marino, R., Mazzucconi, M. G., Molinari, A. C., Morfini, M., Notarangelo, L. D., Peccarisi, L., Peyvandi, F., Pollio, B., Rivolta, G. F., Ruggieri, M. P., Sargentini, V., Schiavoni, M., Sciacovelli, L., Serino, M. L., Siragusa, S., Tagliaferri, A., Testa, S., Tosetto, A., Zampogna, S., and Zanon, E.

Subjects
Factor VIII, FVIII inhibitor, Settore BIO/12, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII, Hemophilia A, Hemorrhage, Hemostatics, Humans, Italy, Quality of Life, FVIII inhibitors, Hemorrhage, Antibodies, Monoclonal, Humanized, Hemophilia A, Antibodies, Hemostatics, bypassing agents, emergency, emicizumab, haemophilia A, Italy, hemic and lymphatic diseases, Monoclonal, Emergency, Haemophilia A, Antibodies, Bispecific, Quality of Life, Humans, Bispecific, Bypassing agents, Emicizumab, Humanized, Bypassing agent, Haemostasis
Abstract

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agent. Given this, and in order to expand the current knowledge on the use of emicizumab and concomitant haemostatic agents, and reduce the risk of complications in this setting, the Italian Association of Haemophilia Centres (AICE) here provides guidance on the management of breakthrough bleeds and surgery in emergency situations in patients with haemophilia A and inhibitors on emicizumab prophylaxis. This paper has been shared with other National Scientific Societies involved in the field.

Published
2020

10. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Author

Santagostino E., Riva A., Cesaro S., Esposito S., Matino D., Mazzucchelli R. I., Molinari, Angelo Claudio, Mura R., Notarangelo L. D., Tagliaferri A., Di Minno G., Clerici M., Ambaglio C., Brigida Aru A., Baldacci E., Barillari G., Basso M., Bernasconi S., Bertamino M., Bertoni E., Biasoli C., Federica Biguzzi E., Bonetti E., Borchiellini A., Bulgarelli S., Cabibbo S., Cantori I., Castaman G., Castiglia P., Coluccia A., Coppetelli U., Coppola A., Cultrera D., De Candia E., Delios G., Di Gennaro L., Di Gregorio P., Di Minno M., Dragani A., Pietro Ettorre C., Franchini M., Galli M., Gallo G., Giordano P., Giuffrida G., Iannaccaro P., Lassandro G., Lazzareschi I., Linari S., Luciani M., Macchi S., Malcangi G., Malizia R., Marietta M., Marino R., Massoud M., Gabriella Mazzucconi M., Milan M., Morfini M., Napolitano M., Pasca S., Pedrazzi P., Peyvandi F. A., Piscitelli L., Pollio B., Preti P., Quintavalle G., Radossi P., Raso S., Ricca I., Rocino A., Santoro C., Carlotta Santoro R., Sarolo L., Schiavoni M., Schiavulli M., Sciancalepore P., Luisa Serino M., Mario Siragusa S., Sottilotta G., Svahn J., Valdre L., Cristina Vedovati M., Zanon E., Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, Angelo Claudio, Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, E., Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, I., Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., and Zanon, E.

Subjects
Adult, medicine.medical_specialty, Consensus, Delphi Technique, Vaccination schedule, Delphi method, haemophilia, 030204 cardiovascular system & hematology, Hemophilia A, Haemophilia, immunization, Hemophilia B, bleeding disorder, factor VIII inhibitor, vaccination, Child, Evidence-Based Medicine, Humans, Italy, Vaccination, 03 medical and health sciences, 0302 clinical medicine, Vaccine administration, Medicine, In patient, Clinical Haemophilia, Genetics (clinical), business.industry, Original Articles, Hematology, General Medicine, Evidence-based medicine, medicine.disease, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Immunization, Family medicine, Original Article, business, 030215 immunology
Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5‐point Likert‐type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence‐ and consensus‐based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Published
2019

23. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Author

Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, Erica, Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, Ilaria, Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., Zanon, E., De Candia E. (ORCID:0000-0003-0942-2819), Lazzareschi I. (ORCID:0000-0001-7221-2983), Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, Erica, Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, Ilaria, Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., Zanon, E., De Candia E. (ORCID:0000-0003-0942-2819), and Lazzareschi I. (ORCID:0000-0001-7221-2983)

Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5-point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence- and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Published
2019

28. The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): A randomized, controlled trial

Author

Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., Lucisano, G., Hegbrant, J., Ariano, R., Lamacchia, O., Sasso, A., Morano, S., Filardi, T., De Cosmo, S., Pugliese, G., Procaccini, D. A., Gesualdo, L., Palasciano, G., Johnson, D. W., Tonelli, M., Strippoli, G. F. M., Cignarelli, M., Di Mauro, M. D., Tonolo, G., Adinolfi, L. E., Gigante, A., Carboni, L., Anichini, R., Marino, C., Querques, M., Manfrini, S., Cianciaruso, B., Grandaliano, Giuseppe, Prato, S. D., Giorgino, F., Perin, P. C., Malberti, F., Nardo, A., Invitti, C., Panettieri, I., Bono-mini, M., Sesti, G., Altomare, E., Giordano, R., Iacono, A., Lusenti, T., Jovane, C., Zavaroni, I., Vernaglione, L., Grosso, J., Stratta, P., Andriani, A., Montanaro, A., Ciaula, A. D., Triolo, G., Santoro, A., Spada, S., Benedetto, A. D., Borzi, V., Tortul, C., Schiavoni, M., Cavalera, C., Iannarelli, R., Mileti, G., Tardi, S., Di Rosa, S., Saglimbene, V, Palmer, Ruospo, S. C., Natale, M., Maione, P., Nicolucci, A., Vecchio, A., Tognoni, M., Craig, G, Pellegrini, J. C., Lucisano, F., Hegbrant, G., Ariano, J., Lamacchia, R., Sasso, O., Morano, A., Filardi, S., Cosmo, De, Pugliese, Pier Paolo, Procaccini, G., Gesualdo, D. A., Palasciano, L., Johnson, G., Tonelli, D. W., Strippoli, M., Cignarelli, G. F. M., Mauro, Di, Tonolo, M. D., G, Adinolfi, Le, Gigante, A., Carboni, L., Anichini, R., Marino, Concetta, Querques, M., Manfrini, Cianciaruso, S., Grandaliano, B., Prato, G., Giorgino, S. D., Perin, F., Malberti, P. C., Nardo, F., Invitti, A. n., Cavalera, C., Iannarelli, C., Mileti, R., Tardi, G., and Rosa, Di

Subjects
Male, Angiotensin-Converting Enzyme Inhibitors, 030204 cardiovascular system & hematology, albuminuria, clinical trial, diabetic nephropathy, end-stage renal disease, mortality, renin angiotensin system, urologic and male genital diseases, law.invention, Renin-Angiotensin System, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, Settore MED/14 - NEFROLOGIA, 030212 general & internal medicine, General Medicine, Middle Aged, Cardiovascular disease, female genital diseases and pregnancy complications, Treatment Outcome, Cardiovascular Diseases, Nephrology, Hypertension, Drug Therapy, Combination, Female, medicine.symptom, medicine.drug, medicine.medical_specialty, Combination therapy, End stage renal disease, Angiotensin Receptor Antagonists, 03 medical and health sciences, Clinical Research, Internal medicine, Diabetes Mellitus, medicine, Albuminuria, Humans, Adverse effect, Aged, business.industry, Discontinuation, Clinical trial, ACE inhibitor, business, chronic kidney disease
Abstract

Background The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear. Methods In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP,130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, doubling of serum creatinine, albuminuria, eGFR, BP, and adverse events. Results Because of slow enrollment, the trial was modified and stopped 41% short of targeted enrollment of 2100 participants, corresponding to 35% power to detect a 25% reduced risk in the primary outcome. Our analysis included 1243 adults, with median follow-up of 2.7 years. Efficacy outcomes were similar between groups (ACE inhibitor versus ARB, ACE inhibitor versus combination, ARB versus combination) as were rates of serious adverse events. The rate of permanent discontinuation for ARB monotherapy (6.3%) was significantly lower than for ACE inhibitor monotherapy (15.7%) or combined therapy (18.3%). Conclusions Patients may tolerate ARB monotherapy better than ACE inhibitor monotherapy. However, data from this trial and similar trials, although as yet inconclusive, show no trend suggesting differences in mortality and renal outcomes with ACE inhibitors or ARBs as dual or monotherapy in patients with albuminuria and diabetes or other cardiovascular risk factors. Copyright © 2018 by the American Society of Nephrology Background The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear. Methods In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP,130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, doubling of serum creatinine, albuminuria, eGFR, BP, and adverse events. Results Because of slow enrollment, the trial was modified and stopped 41% short of targeted enrollment of 2100 participants, corresponding to 35% power to detect a 25% reduced risk in the primary outcome. Our analysis included 1243 adults, with median follow-up of 2.7 years. Efficacy outcomes were similar between groups (ACE inhibitor versus ARB, ACE inhibitor versus combination, ARB versus combination) as were rates of serious adverse events. The rate of permanent discontinuation for ARB monotherapy (6.3%) was significantly lower than for ACE inhibitor monotherapy (15.7%) or combined therapy (18.3%). Conclusions Patients may tolerate ARB monotherapy better than ACE inhibitor monotherapy. However, data from this trial and similar trials, although as yet inconclusive, show no trend suggesting differences in mortality and renal outcomes with ACE inhibitors or ARBs as dual or monotherapy in patients with albuminuria and diabetes or other cardiovascular risk factors.

Published
2018

29. OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE

Author

Lopetuso, L.R., primary, Quagliariello, A., additional, Schiavoni, M., additional, Petito, V., additional, Ponziani, F., additional, Cammarota, G., additional, Putignani, L., additional, Scaldaferri, F., additional, and Gasbarrini, A., additional

Published
2019
Full Text
View/download PDF

30. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Author

Di Nisio M, Baudo F, D'Angelo A, De Gasperi A, Malato A, Schiavoni M, Squizzato A, Italian Society for Thrombosis, Haemostasis, COSMI, BENILDE, Di Nisio M, Baudo F, Cosmi B, D'Angelo A, De Gasperi A, Malato A, Schiavoni M, Squizzato A, and Italian Society for Thrombosis and Haemostasis.

Subjects
medicine.medical_specialty, medicine.drug_class, Low molecular weight heparin, Guidelines, Neoplasms, hemic and lymphatic diseases, Internal medicine, medicine, Humans, disseminated intravascular coagulation, Disseminated intravascular coagulation, Prothrombin time, biology, medicine.diagnostic_test, business.industry, Septic shock, Antithrombin, Venous Thromboembolism, Hematology, medicine.disease, Surgery, diagnosi, Treatment Outcome, Italy, Recombinant factor VIIa, Cryoprecipitate, biology.protein, Fresh frozen plasma, business, circulatory and respiratory physiology, medicine.drug
Abstract

Background The diagnosis and treatment of disseminated intravascular coagulation (DIC) remain extremely controversial. Purpose The Italian Society for Thrombosis and Haemostasis commissioned a project to develop clinical practice guidelines for the diagnosis and treatment of DIC. Methods Key questions about the diagnosis and treatment of DIC were formulated by a multidisciplinary working group consisting of experts in clinical medicine and research. After a systematic review and discussion of the literature, recommendations were formulated and graded according to the supporting evidence. In the absence of evidence, evidence of low quality, or contradictory evidence, a formal consensus method was used to issue clinical recommendations. Results and Conclusions In suspected DIC, we suggest the use of the diagnostic scores ISTH (grade C), JMHW (grade C) or JAAM (grade D) over stand alone tests. The cornerstone of the management of DIC remains the treatment of the underlying triggering disease. We do not suggest the use of antithrombin (grade D), dermatan sulphate (grade D), gabexate (grade D), recombinant factor VIIa (grade D), activated protein C (grade D), thrombomodulin (grade B). The use of unfractionated heparin or low-molecular-weight heparin is not suggested except for thromboembombolic prophylaxis in patients a high risk who do not have active bleeding (grade D). In patients with severe sepsis/septic shock and DIC we suggest the use of human recombinant activated protein C (grade D). In patients with DIC and active bleeding we suggest the use of transfusion therapy (platelets, plasma, cryoprecipitate) (grade D).

Published
2012

31. DILATED CARDIOMYOPATHY AND THERAPEUTIC FOLLOW–UP: EXPERIENCE OF A DEDICATED HEART FAILURE CLINIC

Author

Dominici, T, Percoco, F, Schiavoni, M, Dato, I, Tung, M, Pontiroli, C, Verbena, S, Evangelista, F, Ciccaglioni, L, Barbato, A, and Kol, A

Abstract

Dilated Cardiomyopathy (DCM)is associated with an increased risk of developing ventricular arrhythmias and sudden cardiac death (SCD), although to a lesser extent than ischemic heart disease (IHD).It is now well established that defibrillator implantation (ICD) reduces mortality in patients with reduced systolic function after a myocardial infarction, conversely, this effect is less evident in patients with DCM. The aim of this work is to report the experience of a dedicated outpatient clinic for heart failure patients and to underline the importance of a multiparametric assessment for a patient who is a candidate for ICD implantation. From December 2019 to December 2023, 38 patients (34 males and 4 females) (mean age 62.6 years) were referred to our hospital with a diagnosis of hypokinetic dilated heart disease of first detection, in 4 cases due to declared alcohol and/or substance abuse.Three patients had already undergone defibrillator implantation in primary prevention but did not have on board the 4 classes of drugs recommended by the latest guidelines, so they were subjected to the maximum tolerated dose and re–evaluated remotely with clinical improvement and echocardiographic values. The other 35 patients, whose disease began with de novo reduced ejection fraction heart failure (HFrEF), admitted to our ICU, all underwent coronary angiography with finding of a coronary tree free of critical alterations; 28 had performed a magnetic resonance imaging (MRI) that showed no edema, necrosis and/or fibrosis; only in two patients have been documented fibrosis with a low percentage of distribution, which does not account for low EF values. Of the other 7 patients, 4 did not undergo MRI 2 for claustrophobia and 3 for atrial fibrillation. Maximal drug therapy with the 4 pillars recommended by the guidelines was set up for all patients;the introduction of glyphozines in diabetic patients has been shared with diabetologist. All patients underwent echocardiographic check–ups at 3–6 months and one year, which over time documented a recovery associated with improvement in symptoms and quality of life. All patients also underwent ECG according to Holter for arrhythmic risk stratification: none of them required ICD implantation procedures. This preliminary analysis shows that a correct application of the guidelines allows to improve the prognosis of patients with dilated cardiomyopathy; of course, further larger studies are needed to substantiate these findings.

Published
2024
Full Text
View/download PDF

33. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey

Author

Franchini, M, Coppola, A, Rocino, A, Zanon, E, Morfini, M, Italian Association of Haemophilia Centers AICE Working Group, Accorsi, A, Aru, Ab, Biasoli, C, Cantori, I, Castaman, G, Cesaro, S, Ciabatta, C, De Cristofaro, R, Delios, G, Di Minno, G, D'Incà, M, Dragani, A, Ettorre, Cp, Gagliano, F, Gamba, G, Gandini, G, Giordano, P, Giuffrida, G, Gresele, P, Latella, C, Luciani, M, Margaglione, M, Marietta, M, Mazzucconi, Maria Gabriella, Messina, M, Molinari, Ac, Notarangelo, Ld, Oliovecchio, E, Peyvandi, F, Piseddu, G, Rossetti, G, Rossi, V, Santagostino, E, Schiavoni, M, Schinco, P, Serino, Ml, Tagliaferri, A, Testa, S., Franchini, M, Coppola, A, Rocino, A, Zanon, E, Morfini, M, Accorsi, A, Aru, Ab, Biasoli, C, Cantori, I, Castaman, G, Cesaro, S, Ciabatta, C, De Cristofaro, R, Delios, G, DI MINNO, Giovanni, D'Incà, M, Dragani, A, Ettorre, Cp, Gagliano, F, Gamba, G, Gandini, G, Giordano, P, Giuffrida, G, Gresele, P, Latella, C, Luciani, M, Margaglione, M, Marietta, M, Mazzucconi, Mg, Messina, M, Molinari, Ac, Notarangelo, Ld, Oliovecchio, E, Peyvandi, F, Piseddu, G, Rossetti, G, Rossi, V, Santagostino, E, Schiavoni, M, Schinco, P, Serino, Ml, Tagliaferri, A, and Testa, S.

Subjects
Haemophilia, Pediatrics, medicine.medical_specialty, factor concentrates, haemophilia treatment, inhibitor, prophylaxis, survey, viral safety, Blood Coagulation Factors, Health Care Surveys, Hemophilia A, Humans, Italy, Practice Patterns, Physicians', Surveys and Questionnaires, Hospitals, Special, Medical Staff, Hospital, Practice Patterns, NO, Hospital, Haemophilia A, Medical Staff, Medicine, Genetics (clinical), Clotting factor, Physicians', Special, Treatment regimen, business.industry, Settore MED/09 - MEDICINA INTERNA, Hematology, General Medicine, medicine.disease, Blood coagulation factors, Hospitals, Clinical Practice, Regimen, Family medicine, Product selection, business
Abstract

Summary Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.

Published
2014

34. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy

Author

Giampaolo A, Abbonizio F, Puopolo M, Arcieri R, Mannucci PM, Hassan HJ, Accorsi A, Ettorre PC, Schiavoni M, Palareti G, Rodorigo G, Valdré L, Amaddii G, Billio A, Notarangelo L, Iannacaro P, Muleo P, Biasioli C, Rossi V, Alatri A, Testa S, Vincenzi D, Scapoli G, Morfini M, Molinari AC, Lapecorella M, Mariani G, Baudo F, Caimi MT, Federici AB, Gringeri A, Santagostino E, Marietta M, Coppola A, Perricone C, Schiavulli M, Miraglia E, Rocino A, Zanon E, Gagliano F, Mancuso G, Siragusa S, Rivolta F, Tagliaferri A, Gamba G, Iorio A, Oliovecchio E, Dragani A, Arbasi MC, Albertini P, Mancino A, Lombardo VT, Latella C, D'Incà M, Landolfi Raffaele, Biondo Francesca, Mazzucconi MG, Santoro Cristina, Mameli AL, Piseddu G, Schinco PC, Messina M, Rossetti G, Barillari G, Feola G, Franchini M, Gandini G, Castaman G, Rodeghiero F, Italian Association of Haemophilia Centres, DI MINNO, GIOVANNI, Giampaolo, A, Abbonizio, F, Puopolo, M, Arcieri, R, Mannucci, Pm, Hassan, Hj, Accorsi, A, Ettorre, Pc, Schiavoni, M, Palareti, G, Rodorigo, G, Valdré, L, Amaddii, G, Billio, A, Notarangelo, L, Iannacaro, P, Muleo, P, Biasioli, C, Rossi, V, Alatri, A, Testa, S, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Lapecorella, M, Mariani, G, Baudo, F, Caimi, Mt, Federici, Ab, Gringeri, A, Santagostino, E, Marietta, M, Coppola, A, DI MINNO, Giovanni, Perricone, C, Schiavulli, M, Miraglia, E, Rocino, A, Zanon, E, Gagliano, F, Mancuso, G, Siragusa, S, Rivolta, F, Tagliaferri, A, Gamba, G, Iorio, A, Oliovecchio, E, Dragani, A, Arbasi, Mc, Albertini, P, Mancino, A, Lombardo, Vt, Latella, C, D'Incà, M, Landolfi, Raffaele, Biondo, Francesca, Mazzucconi, Mg, Santoro, Cristina, Mameli, Al, Piseddu, G, Schinco, Pc, Messina, M, Rossetti, G, Barillari, G, Feola, G, Franchini, M, Gandini, G, Castaman, G, Rodeghiero, F, and Italian Association of Haemophilia, Centres

Subjects
Clotting factor, Male, Pediatrics, medicine.medical_specialty, Factor VIII, business.industry, Haemophilia A, Hematology, Disease, medicine.disease, Haemophilia, Hemophilia A, Hemophilia B, Factor IX, On demand treatment, Coagulation, Italy, Surveys and Questionnaires, medicine, Humans, Female, National registry, business, Coagulation Disorder
Abstract

Dear Sir, Treatment of haemophilia is costly, and it must be carefully monitored by physicians and health authorities, so as to improve the planning of the supply of factor concentrates obtained from the fractionation of human plasma or by recombinant technology. Therapy with coagulation factors can be used either prophylactically to prevent bleeding, which entails multiple weekly infusions, or on-demand, through infusion of the amount of factors determined by the severity of the disease and patient’s weight, to stop ongoing bleeding. According to a recent study, factor VIII (FVIII) consumption among persons with haemophilia A (HA) has increased in countries with high-income economies (Stonebraker et al., 2010). In Italy, haemophiliacs and other persons with congenital coagulation disorders are monitored by the National Registry of Congenital Coagulopathies (NRCC) established at the Istituto Superi=

Published
2011

35. Evidence-based recommendations on the treatment of von Willebrand disease in Italy

Author

Mannucci, Pm, Franchini, M, Castaman, G, Federici, Ab, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdre, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Boeri, E, Caprino, D, Delios, G, Girotto, M, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Marietta, M, Pedrazzoli, P, Di Minno, G, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Iorio, A, Oliovecchio, E, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, D'Incà, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Maria Gabriella, Santoro, Cristina, Piseddu, G, Schinco, Pc, Rossetti, G, Barillari, G, Feola, G, Gandini, G., Mannucci, Pm, Franchini, M, Castaman, G, Federici, Ab, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdre, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Boeri, E, Caprino, D, Delios, G, Girotto, M, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Marietta, M, Pedrazzoli, P, DI MINNO, Giovanni, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Iorio, A, Oliovecchio, E, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, D'Incà, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Mg, Santoro, C, Piseddu, G, Schinco, Pc, Rossetti, G, Barillari, G, Feola, G, and Gandini, G.

Subjects
Male, desmopressin, Evidence-Based Medicine, Factor VIII, Hemostatics, von willebrand disease, von Willebrand Diseases, von willebrand factor, Treatment Outcome, Italy, von Willebrand Factor, Humans, Deamino Arginine Vasopressin, Drug Therapy, Combination, Female, Original Article
Abstract

von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII).This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease.Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.

Published
2009

36. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy

Author

Rocino, A., Coppola, A., Franchini, M., Castaman, G., Santoro, C., Zanon, E., Santagostino, E., Morfini, M., Accorsi, A., Brigida Aru, A., Biasoli, C., Cantori, I., Cesaro, S., Ciabatta, C., De Cristofaro, R., Delios, G., Di Minno, G., D'Incà, M., Dragani, A., Pietro Ettorre, C., Gagliano, F., Gamba, G., Gandini, G., Giordano, P., Giuffrida, G., Gresele, P., Jane Hassan, H., Latella, C., Luciani, M., Margaglione, M., Marietta, M., Gabriella Mazzucconi, M., Messina, M., Claudio Molinari, A., Dora Notarangelo, L., Peyvandi, F., Piseddu, G., Rossetti, G., Rossi, V., Carlotta Santoro, R., Schiavoni, M., Schinco, P., Luisa Serino, M., Tagliaferri, A., Testa, S., Rocino, A, Coppola, A, Franchini, M, Castaman, G, Santoro, C, Zanon, E, Santagostino, E, Morfini, M, and DI MINNO, Giovanni

Subjects
therapy, Settore MED/09 - Medicina Interna, congenital bleeding disorders, haemophilia with inhibitors, haemophilia, prophylaxis, Hematology, Immunology and Allergy, Recommendation
Published
2014

38. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis

Author

IORIO A, OLIOVECCHIO E, MORFINI M, MANNUCCI PM, CONTINO L, ACCORSI A, CIAVARELLA N, SCHIAVONI M, SCARAGGI FA, RODORIGO G, VALDRÉ L, TARGHETTA R, TAGARIELLO G, RADOSSI P, MUSSO R, CULTRERA D, MULEO G, IANNACARO P, BIASIOLI C, TESTA S, ALATRI A, VINCENZI D, SCAPOLI G, MOLINARI AC, BOERI E, CAPRINO D, MARIANI G, LAPECORELLA M, CARLONI MT, CANTORI I, SANTAGOSTINO E, GRINGERI A, FEDERICI AB, MARIETTA M, PEDRAZZOLI P, DI MINNO G, PERRICONE C, SCHIAVULLI M, ROCINO A, BERRETTINI M, ZANON E, MANCUSO G, TAGLIAFERRI A, RIVOLTA F, FERRANTE F, DRAGANI A, ROSSI A, ALBERTINI P, MACCHI S, D'INCA M, DE ROSSI G, LUCIANI M, LANDOLFI R, MAZZUCCONI MG, SANTORO C, PISEDDU G, CARLA SCHINCO P, ROSSETTI G, BARILLARI G, FEOLA G, GANDINI G, FRANCHINI M, CASTAMAN G., COPPOLA, Antonino, SIRAGUSA, Sergio, MALATO, Alessandra, SACCULLO, Giorgia, MANCINO, Antonio, IORIO A, OLIOVECCHIO E, MORFINI M, MANNUCCI PM, CONTINO L, ACCORSI A, CIAVARELLA N, SCHIAVONI M, SCARAGGI FA, RODORIGO G, VALDRÉ L, TARGHETTA R, TAGARIELLO G, RADOSSI P, MUSSO R, CULTRERA D, MULEO G, IANNACARO P, BIASIOLI C, TESTA S, ALATRI A, VINCENZI D, SCAPOLI G, MOLINARI AC, BOERI E, CAPRINO D, MARIANI G, LAPECORELLA M, CARLONI MT, CANTORI I, SANTAGOSTINO E, GRINGERI A, FEDERICI AB, MARIETTA M, PEDRAZZOLI P, DI MINNO G, COPPOLA A, PERRICONE C, SCHIAVULLI M, ROCINO A, BERRETTINI M, ZANON E, MANCUSO G, SIRAGUSA S, MALATO A, SACCULLO G, TAGLIAFERRI A, RIVOLTA F, FERRANTE F, DRAGANI A, ROSSI A, MANCINO A, ALBERTINI P, MACCHI S, D'INCA M, DE ROSSI G, LUCIANI M, LANDOLFI R, MAZZUCCONI MG, SANTORO C, PISEDDU G, CARLA SCHINCO P, ROSSETTI G, BARILLARI G, FEOLA G, GANDINI G, FRANCHINI M, and CASTAMAN G

Subjects
methodology, haemophilia, Settore MED/15 - Malattie Del Sangue
Published
2008

39. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis

Author

Iorio, A, Oliovecchio, E, Morfini, M, Mannucci, Pm, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdré, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Molinari, Ac, Boeri, E, Caprino, D, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Federici, Ab, Marietta, M, Pedrazzoli, P, Di Minno, G, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, Hassan, J, D'Inca, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Maria Gabriella, Santoro, Cristina, Piseddu, G, Carla Schinco, P, Rossetti, G, Barillari, G, Feola, G, Gandini, G, Franchini, M, Castaman, G., Iorio, A, Oliovecchio, E, Morfini, M, Mannucci, Pm, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdré, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Molinari, Ac, Boeri, E, Caprino, D, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Federici, Ab, Marietta, M, Pedrazzoli, P, DI MINNO, Giovanni, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, Hassan, J, D'Inca, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Mg, Santoro, C, Piseddu, G, Carla Schinco, P, Rossetti, G, Barillari, G, Feola, G, Gandini, G, Franchini, M, and Castaman, G.

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Haemophilia A, MEDLINE, Haemophilia, Severity of Illness Index, haemophilia, registry, von willebrand's disease, von willebrand’s disease, Blood Coagulation Disorders, Inherited, Von willebrand, Severity of illness, Health care, Computer software, medicine, Humans, Haemophilia B, Registries, Age of Onset, Child, Genetics (clinical), Societies, Medical, Aged, business.industry, Infant, Hematology, General Medicine, Middle Aged, medicine.disease, Databases as Topic, Italy, Child, Preschool, Data Interpretation, Statistical, Female, Medical emergency, business
Abstract

National haemophilia registries are powerful instruments to support health care and research. A national registry was established in Italy by the Ministry of Health until 1999. Since 2003 the Italian Association of Haemophilia Centres (AICE) started a new programme aiming at building up the Italian Registry of Haemophilia and Allied Disorders. The AICE identified an expert panel to steer the registry. A computer software to assist patient management was developed and all the AICE-affiliated haemophilia treatment centres (HTC) were prompted to adopt it. Twice a year a predefined set of anonymized data is centralized and merged into a national database. Duplicated entries are managed through a confidentiality sparing mechanism. The database covers sociodemographic, clinical, laboratory and treatment data. A subset of data are shared with the Ministry of Health (Istituto Superiore di Sanita,ISS).Overall, data were collected six times by 43 of 49 HTC; 41 centres updated their patients' records up to December 2006. The database contains 6632 unique records, 442 of them referring to dead patients. Database growth and missing data clearance showed a constantly positive trend over time. The database has collected records of the following alive patients - haemophilia A: 1364 severe, 398 moderate and 935 mild; haemophilia B: 231 severe, 138 moderate and 204 mild; von Willebrand's disease: 1208 type 1, 346 type 2 and 96 type 3. Inhibitor patients were 296 (of which 194 high responders and 65 low responders).The Italian registry run by AICE adds to the list of the available national haemophilia registries and is intended to establish treatment guidelines and foster research projects in Italy.

Published
2008

40. Anti-Glare Effect of Deeply Textured Cover Glasses for Solar Modules for Installations Close to Airports and Heliports

Author

Schiavoni, M., Gayout, P., Berard, M., Nositschka, W.A., Neumann, D., and Nicklas, D.

Subjects
COMPONENTS FOR PV SYSTEMS, PV Modules
Abstract

28th European Photovoltaic Solar Energy Conference and Exhibition; 3069-3072, In this work we show that deeply textured glass covers can solve an important issue which is the risk of glare due to sunlight reflection on PV modules. We introduce a quantitative measure of glare as the luminance value in the brightest direction and we observe that SGGAlbarino P glass covers allow a reduction of more than 2 orders of magnitude compared to reference smoothly textured cover glasses, from more than one million cd/m² to less than ten thousand cd/m². The physical explanation of this extremely efficient anti-glare property of SGGAlbarino P is to be found in its surface topography which shows both a very broad slope distribution and a randomized aspect.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results